NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
PMV Pharmaceuticals reported its financial results for Q4 and full year 2023, highlighting the progress of rezatapopt and an extended cash runway.
PMV Pharmaceuticals reported its full year 2023 financial results, with a focus on the advancement of rezatapopt and the extension of the company's cash runway to the end of 2026 through cost savings initiatives. The registrational Phase 2 clinical trial for rezatapopt remains on track to initiate in Q1 2024.
- Registrational Phase 2 clinical trial of rezatapopt remains on track to initiate in Q1 2024.
- Phase 1 analysis of rezatapopt in ovarian cancer patients selected for presentation at the 2024 SGO Annual Meeting.
- Updated Phase 1 data demonstrated responses across multiple tumor types with a 38% overall response rate.
- Cash, cash equivalents, and marketable securities totaled $228.6 million as of December 31, 2023, with runway extended to the end of 2026.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
PMV Pharma is focused on advancing the rezatapopt clinical program and has extended its cash runway to the end of 2026.
Tailwinds
- Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt remains on track to initiate in Q1 2024
- Phase 1 analysis from the PYNNACLE Phase 1/2 study of rezatapopt in a subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation selected as a late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer
- Cost savings from January 2024 workforce reduction expected to extend cash runway to end of 2026
- Alignment with FDA on RP2D and key elements of single arm, tumor agnostic Phase 2 registrational portion of PYNNACLE study
- Initiated enrollment in the combination arm of the PYNNACLE study with rezatapopt and KEYTRUDA® (pembrolizumab).
Headwinds
- The company is still operating at a loss
- Workforce reduction to extend cash runway
- Clinical trials are subject to risks and uncertainties
- The company's ability to fund operations
- Impact that any current or future global pandemic or geopolitical emergency may have on the Company’s clinical trials, supply chain, and operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro